RedPath Inks Contract with MultiPlan for Pancreatic Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – RedPath Integrated Pathology today announced the execution of an agreement with preferred provider organization MultiPlan for RedPath's PathFinder TG test for pancreatic cancer.

The contract is the seventh inked by the Pittsburgh-based molecular diagnostics firm with a national PPO and expands the number of covered lives for the test to more than 74 million people, RedPath said. PathFinder TG produces mutational profiles to help physicians "resolve complex diagnostic dilemmas in patients who are at risk of cancer."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.